This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lee, M. A Articles by Tiernan, E. J J Search for Related Content PubMed PubMed Citation Articles by Lee, M. A Articles by Tiernan, E. J J Social Bookmarking                         What's this?

Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine

Mhoira E F Leng

Eóin J J Tiernan

An uncontrolled retrospective study was conducted looking at the use of oral controlled-release hydromorphone in palliative care patients. Over a 2-year period 55 patients were switched to hydromorphone therapy, and the efficacy and outcomes were assessed. Urea and electrolyte measurements were also recorded at the time of opioid switch and renal impairment defined as urea > 10.5 mmol/l and/or creatinine [.greaterequal] 101 mmol/l. This group of 29 patients with abnormal urea and/or creatinine (Group 1) was compared with the remaining 26 patients (Group 2) who had normal urea and creatinine.

The major reasons for change to hydromorphone were side-effects (cognitive/ drowsiness/nausea) on previous therapy. Following a switch to hydromorphone these side-effects improved in over 80% of patients (n = 55). Comparison between Group 1 and 2 demonstrated a significant difference in renal function but no significant differences in reasons for change, dose of opioids or response to change (over 80% improvement following opioid switch).

We conclude that hydromorphone is a flexible second-line alternative to morphine that is particularly useful when intolerable side-effects are experienced with other opioids. In renal impairment (including two patients with end-stage renal failure) we found hydromorphone to be safe and effective. Further clinical and pharmacokinetic studies are required.

Key Words: hydromorphone • metabolites • renal impairment • palliative care • side effects

Palliative Medicine, Vol. 15, No. 1, 26-34 (2001)
DOI: 10.1191/026921601669626431


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C Douglas, F. Murtagh, E. Chambers, M Howse, and J Ellershaw Symptom management for the adult patient dying with advanced chronic kidney disease: A review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group Palliative Medicine, March 1, 2009; 23(2): 103 - 110. [Abstract] [PDF]